Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function

Hypertension

Volumn 57, Issue 4, 2011, Pages 746-754

  Lother, Achim ^a   Berger, Stefan ^b   Gilsbach, Ralf ^a   Rösner, Stephan ^a   Ecke, Andreas ^a   Barreto, Frederico ^a   Bauersachs, Johann ^c   Schütz, Günther ^b   Hein, Lutz ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

cardiac hypertrophy; cardiac pressure overload; fibrosis; mineralocorticoid receptor; transgenic mouse model

Indexed keywords

ATRIAL NATRIURETIC FACTOR; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN BETA; PROTEIN KINASE B; S6 KINASE; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; HEART DILATATION; HEART FAILURE; HEART FUNCTION; HEART HYPERTROPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE OVERLOAD; HEART LEFT VENTRICLE PRESSURE; HEART LEFT VENTRICLE SIZE; HEART LEFT VENTRICLE WALL; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE TENSION; HEART PROTECTION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; FIBROSIS; HEART FAILURE; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE; MICE, TRANSGENIC; MYOCARDIUM; MYOCYTES, CARDIAC; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION;

EID: 79953224745     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.163287     Document Type: Article

References (30)

1. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321. (Pubitemid 36384098)
2. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717. (Pubitemid 29407370)
3. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J. 2009;30:469-477.
4. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992;120:893-901. (Pubitemid 23002899)
5. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol. 1995;269: E657-E662.
6. Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol. 2003; 42:1666-1673. (Pubitemid 37378451)
7. Kuster GM, Kotlyar E, Rude MK, Siwik DA, Liao R, Colucci WS, Sam F. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005;111:420-427. (Pubitemid 40204425)
8. Vallon V, Wyatt AW, Klingel K, Huang DY, Hussain A, Berchtold S, Friedrich B, Grahammer F, Belaiba RS, Gorlach A, Wulff P, Daut J, Dalton ND, Ross J Jr, Flogel U, Schrader J, Osswald H, Kandolf R, Kuhl D, Lang F. SGK1-dependent cardiac CTGF formation and fibrosis following DOCA treatment. J Mol Med. 2006;84:396-404. (Pubitemid 43673614)
9. Chai W, Danser AH. Why are mineralocorticoid receptor antagonists cardioprotective? Naunyn Schmiedebergs Arch Pharmacol. 2006;374: 153-162. (Pubitemid 44819249)
10. Le Menuet D, Isnard R, Bichara M, Viengchareun S, Muffat-Joly M, Walker F, Zennaro MC, Lombes M. Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor. J Biol Chem. 2001;276:38911-38920.
11. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, Perrier R, Soukaseum C, Cat AN, Royer A, Le Quang K, Charpentier F, Demolombe S, Mechta-Grigoriou F, Beggah AT, Maison-Blanche P, Oblin ME, Delcayre C, Fishman GI, Farman N, Escoubet B, Jaisser F. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005;111:3025-3033. (Pubitemid 40847778)
12. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ, Funder JW, McMahon EG. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res. 2003;93:69-76. (Pubitemid 36859043)
13. Messaoudi S, Milliez P, Samuel JL, Delcayre C. Cardiac aldosterone overexpression prevents harmful effects of diabetes in the mouse heart by preserving capillary density. FASEB J. 2009;23:2176-2185.
14. Ambroisine ML, Favre J, Oliviero P, Rodriguez C, Gao J, Thuillez C, Samuel JL, Richard V, Delcayre C. Aldosterone-induced coronary dysfunction in transgenic mice involves the calcium-activated potassium (BKCa) channels of vascular smooth muscle cells. Circulation. 2007;116: 2435-2443. (Pubitemid 350145078)
15. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension. 2009;54:537-543.
16. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schutz G, Lumeng CN, Mortensen RM. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest. 2010;120:3350-3364.
17. Berger S, Wolfer DP, Selbach O, Alter H, Erdmann G, Reichardt HM, Chepkova AN, Welzl H, Haas HL, Lipp HP, Schutz G. Loss of the limbic mineralocorticoid receptor impairs behavioral plasticity. Proc Natl Acad Sci USA. 2006;103:195-200. (Pubitemid 43076127)
18. Ludwig A, Budde T, Stieber J, Moosmang S, Wahl C, Holthoff K, Langebartels A, Wotjak C, Munsch T, Zong X, Feil S, Feil R, Lancel M, Chien KR, Konnerth A, Pape HC, Biel M, Hofmann F. Absence epilepsy and sinus dysrhythmia in mice lacking the pacemaker channel HCN2. EMBO J. 2003;22:216-224. (Pubitemid 36119427)
19. Wettschureck N, Rutten H, Zywietz A, Gehring D, Wilkie TM, Chen J, Chien KR, Offermanns S. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of G-q/G-11 in cardiomyocytes. Nat Med. 2001;7:1236-1240.
20. Florin L, Alter H, Grone HJ, Szabowski A, Schutz G, Angel P. Cre recombinase-mediated gene targeting of mesenchymal cells. Genesis. 2004;38:139-144. (Pubitemid 38506851)
21. Beetz N, Harrison MD, Brede M, Zong X, Urbanski MJ, Sietmann A, Kaufling J, Barrot M, Seeliger MW, Vieira-Coelho MA, Hamet P, Gaudet D, Seda O, Tremblay J, Kotchen TA, Kaldunski M, Nusing R, Szabo B, Jacob HJ, Cowley AW Jr, Biel M, Stoll M, Lohse MJ, Broeckel U, Hein L. Phosducin influences sympathetic activity and prevents stress-induced hypertension in humans and mice. J Clin Invest. 2009;119:3597-3612.
22. Gilsbach R, Schneider J, Lother A, Schickinger S, Leemhuis J, Hein L. Sympathetic-(2)-adrenoceptors prevent cardiac hypertrophy and fibrosis in mice at baseline but not after chronic pressure overload. Cardiovasc Res. 2010;86:432-442.
23. Kawahara Y, Tanonaka K, Daicho T, Nawa M, Oikawa R, Nasa Y, Takeo S. Preferable anesthetic conditions for echocardiographic determination of murine cardiac function. J Pharmacol Sci. 2005;99:95-104. (Pubitemid 41366896)
24. Yamakawa H, Imamura T, Matsuo T, Onitsuka H, Tsumori Y, Kato J, Kitamura K, Koiwaya Y, Eto T. Diastolic wall stress and ANG II in cardiac hypertrophy and gene expression induced by volume overload. Am J Physiol Heart Circ Physiol. 2000;279:H2939-H2946. (Pubitemid 32005884)
25. Ronzaud C, Loffing J, Bleich M, Gretz N, Grone HJ, Schutz G, Berger S. Impairment of sodium balance in mice deficient in renal principal cell mineralocorticoid receptor. J Am Soc Nephrol. 2007;18:1679-1687. (Pubitemid 46870305)
26. Chai W, Garrelds IM, Arulmani U, Schoemaker RG, Lamers JM, Danser AH. Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective? Br J Pharmacol. 2005; 145:664-671. (Pubitemid 41032638)
27. Takaoka H, Esposito G, Mao L, Suga H, Rockman HA. Heart sizeindependent analysis of myocardial function in murine pressure overload hypertrophy. Am J Physiol Heart Circ Physiol. 2002;282:H2190-H2197. (Pubitemid 34663030)
28. Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng CF, Kitsis RN, Molkentin JD. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 2000;19:6341-6350.
29. Kehat I, Molkentin JD. Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy. Ann N Y Acad Sci. 2010; 1188:96-102.
30. Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N, Vallon V. (Patho)physiological significance of the serum-and glucocorticoidinducible kinase isoforms. Physiol Rev. 2006;86:1151-1178. (Pubitemid 44521650)